Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.60 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9206095 | 1.00 | MTNR1A (0.60) | MTNR1AFFAR1GAAMAPTPOLB | |
| Hydrochloric Acid SCHEMBL7829817 | 0.98 | MTNR1A (0.58) | MTNR1AFFAR1GAAMAPTPOLB | |
| Hydrochloric Acid SCHEMBL7829814 | 0.98 | MTNR1A (0.58) | MTNR1AFFAR1GAAMAPTPOLB | |
| SCHEMBL21198181 | 0.87 | NPC1 (0.49) | MTNR1AFFAR1MAPTALDH1A1MEN1 | |
| SCHEMBL6982719 | 0.85 | MTNR1A (0.63) | MTNR1AFFAR1GAAMAPTPOLB | |
| SCHEMBL7199006 | 0.85 | MTNR1A (0.60) | MTNR1AFFAR1GAAMAPTPOLB | |
| SCHEMBL29444764 | 0.85 | MTNR1A (0.63) | MTNR1AFFAR1GAAMAPTPOLB | |
| SCHEMBL1870686 | 0.85 | MTNR1A (0.63) | MTNR1AFFAR1GAAMAPTPOLB | |
| SCHEMBL11219443 | 0.82 | MTNR1A (0.64) | MTNR1AFFAR1GAAMAPTPOLB | |
| Hydrochloric Acid SCHEMBL7825070 | 0.81 | MTNR1A (0.59) | MTNR1AFFAR1GAAMAPTALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070117788-A1 | Combination of a dopamine D2-receptor agonist and tiotropium or a derivative therof for treating obstructive airways and other inflammatory diseases | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-05-24 | — | — | US | disclosed |
| EP-0520674-B1 | Antipsychotic benzodioxan derivatives | AMERICAN HOME PROD (US) | 1995-08-16 | — | — | EP | disclosed |
| EP-0658160-A1 | ANTIPSYCHOTIC QUINOLINE DERIVATIVES OF BENZODIOXANMETHYLAMINE | AMERICAN HOME PRODUCTS CORPORATION (US) | 1995-06-21 | — | — | EP | disclosed |
| WO-1994005655-A1 | ANTIPSYCHOTIC QUINOLINE DERIVATIVES OF BENZODIOXANMETHYLAMINE | AMERICAN HOME PRODUCTS CORPORATION (US) | 1994-03-17 | — | — | WO | disclosed |
| US-5235055-A | Antipsychotic quinoline derivatives of benzodioxanmethylamine | AMERICAN HOME PRODUCTS CORPORATION (US) | 1993-08-10 | — | — | US | disclosed |
| US-5189171-A | Antipsychotic benzodioxan derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1993-02-23 | — | — | US | disclosed |
| EP-0520674-A1 | Antipsychotic benzodioxan derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-12-30 | — | — | EP | disclosed |
| US-5166367-A | Anxiolytic agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-11-24 | — | — | US | disclosed |
| US-5126366-A | Antidepressants, antipsychotics, anxiolytic agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-06-30 | — | — | US | disclosed |
| US-4206125-A | ADENERGIC BLOCKING AGENTS, HYPOTENSIVES | RICHARDSON-MERRELL INC. (US) | 1980-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117788-A1 | Combination of a dopamine D2-receptor agonist and tiotropium or a derivative therof for treating obstructive airways and other inflammatory diseases | CHRM2, ADRB2, CHRM3 | MTNR1A 36/4885FFAR1 969/4885GAA 1864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.